Amgen and AstraZeneca Announce Positive Phase 3 Results for TEZSPIRE in EoE Treatment

Key Facts

In a move that strengthens the position of major players in the biopharmaceutical sector, Amgen and AstraZeneca announced positive top-line results from the Phase 3 CROSSING trial of TEZSPIRE for patients with eosinophilic esophagitis (EoE). According to reports, the drug demonstrated statistically significant and clinically meaningful improvements in disease severity and symptoms compared to placebo through week 52. These results support the broad potential of TEZSPIRE as a treatment for a third epithelial-driven inflammatory disease, significantly expanding its potential market application.

This clinical success comes as major pharmaceutical stocks maintain steady levels, with AMGN shares closing at $442.24 (close August 25, 2026) after reaching a daily high of $447.03. Meanwhile, AstraZeneca (AZN) shares stood at $166.27 (close August 26, 2026) per market data. The positive trial data for a mega-cap pharmaceutical product typically signals future regulatory progress and revenue growth, providing a bullish backdrop for these instruments within the biotech sector.

Traders are monitoring current price levels, with AMGN trading near its recent daily low of $441.26 (close August 25, 2026). While the upcoming economic calendar does not feature immediate sector-specific catalysts, broader market sentiment remains influenced by recent data such as US Initial Jobless Claims, which previously came in at 206k. Investors will be watching for further regulatory filings following these successful Phase 3 results.